Anika Therapeutics Inc. ANIK

Healthcare — Drug Manufacturers Specialty & Generic

Insider Buys (last 12m)

Insider Buys alert about insiders buying in the last 12 month

Overview Business Profile Analyst Commentary Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Quarterly (Descending) Quarterly (Ascending) Annual (Descending) Annual (Ascending) TTM (Descending) TTM (Ascending)

Financial statements are limited to most recent four years or quarters for non-powerpack users

Ten years worth of data (where available), most important trends and XLS exports are available for our Powerpack users.

	Mar '16	Jun '16	Sep '16	Dec '16	Mar '17	Jun '17	Sep '17	Dec '17	Mar '18	Jun '18	Sep '18	Dec '18	Mar '19	Jun '19	Sep '19	Dec '19	Mar '20	Jun '20	Sep '20	Dec '20	Mar '21	Jun '21	Sep '21	Dec '21	Mar '22	Jun '22	Sep '22	Dec '22	Mar '23	Jun '23	Sep '23	Dec '23	Mar '24	Jun '24	Sep '24	Dec '24	Mar '25	Jun '25	Sep '25	Dec '25	Mar '26	Jun '26
P/E ratio	19.61	22.83	19.94	22.57	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡
P/S ratio	6.67	7.61	6.63	7.12	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
P/FCF ratio	23.27	55.74	47.63	70.51	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡‡‡
P/Operating CF	82.70	(801.96)	61.84	121.21	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
P/B ratio	3.40	3.85	3.26	3.30	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Price to Tangible BV	3.79	4.08	3.58	3.58	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
EV/Sales	5.51	6.54	5.49	5.91	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
EV/EBITDA	9.62	11.61	9.88	11.24	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡
EV/Operating CF	12.50	21.07	16.80	24.99	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
EV/FCF	19.22	47.85	39.45	58.56	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Quick Ratio	12.02	12.95	18.73	17.32	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Current Ratio	13.61	14.70	21.22	19.37	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Net Debt/EBITDA	(9.94)	(7.74)	(8.26)	(9.11)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Debt/Assets	0.00%	0.00%	0.00%	0.00%	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡
Debt/Equity	0.00	0.00	0.00	0.00	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡
Asset Turnover	0.48	0.48	0.47	0.43	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Operating CF/Net income	1.17	(0.11)	1.26	0.75	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Capex/Depreciation	(6.81)	(3.60)	(3.13)	(1.47)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Interest Coverage	0.00	0.00	0.00	0.00	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡
Research and Development Expense of Revenue	9.69%	10.50%	10.94%	10.30%	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Selling, General and Administrative Expense of Revenue	17.91%	16.01%	16.60%	19.10%	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Intangible Assets out of Total Assets	0.09	0.05	0.08	0.07	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Share Based Compensation of Revenue	3.67%	2.49%	3.09%	3.88%	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Graham Net Nets	0.19	0.17	0.21	0.21	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Graham Number	25.96	27.14	28.15	27.53	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡
Earnings Yield	5.10%	4.38%	5.02%	4.43%	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Free Cash Flow Yield	4.30%	1.79%	2.10%	1.42%	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Revenue per Share	1.50	1.81	1.76	1.96	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Operating CF per Share	0.54	(0.07)	0.77	0.41	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Capex per Share	(0.43)	(0.24)	(0.19)	(0.10)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Free Cash Flow per Share	0.11	(0.30)	0.59	0.32	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Cash per Share	7.79	7.60	8.23	8.50	‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Shareholders Equity per Share	13.13	13.93	14.67	15.17	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Interest Debt per Share	0.00	0.00	0.00	0.00	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡
Book value per Share	13.13	13.93	14.67	15.17	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Free Cash Flow	1.63	(4.43)	8.58	4.66	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Working Capital	137.04	144.12	153.49	161.64	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Capital Expenditures	(6.42)	(3.45)	(2.74)	(1.41)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Net Current Asset Value	128.81	136.32	144.56	152.97	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Average Receivables	15.41	21.88	22.60	24.63	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Average Payables	2.52	2.48	2.08	5.30	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Average Inventory	14.14	14.49	15.05	15.46	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Average Assets	206.07	215.38	226.96	238.00	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Average Common Equity	188.59	197.49	207.15	216.81	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
EV/EBIT	10.30	12.43	10.55	12.07	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡
Capex to Sales	0.29	0.13	0.11	0.05	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Net Profit Margin	30.94%	32.41%	34.71%	28.15%	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Price to Operating Income	12.47	14.48	12.74	14.54	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡

Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Subscribe now